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Objectives: To evaluate characteristics of Streptococcus pneumoniae associated with orophar-
yngeal colonization in the Ugandan adult HIV population.
Methods: We conducted a cross-sectional study at the outpatient HIV clinic at the Joint Clinical
Research Centre in Kampala, Uganda between July 2004 and February 2005. Six hundred HIV-
infected individuals were interviewed and had oropharyngeal specimens collected. Pneumococci
were isolated from these specimens and antimicrobial susceptibility patterns determined using
standard microdilution methods. Serotypes of the pneumococcal isolates were evaluated by
capsular swelling reaction with commercial antisera.
Results: The prevalence of oropharyngeal colonization with pneumococci was 18% (108/600).
Thirty-two different pneumococcal serotypes were identified, and the most common were ser-
otypes 3 (14.7%), 19F (6.4%), 23F (6.4%), and 16 (5.5%). Seventy-two percent of the isolates were
penicillin (PCN) intermediate (MICs 0.12—1 mg/mL), the remainder all being PCN susceptible, and§ This study was presented in part as a poster at the Infectious Diseases Society of America Conference 2005 in San Francisco, CA, USA.
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Streptococcus pneumoniae is a major cause of acute otitis
media, sinusitis, pneumonia, bacteremia, and meningitis
throughout the world.1 In the pre-treatment era, approxi-
mately 80% of patients hospitalized with pneumococcal
bacteremia died of their infections.2 For over a half-century
in the developed world, however, patients with pneumococ-
cal disease have benefited from penicillin and other anti-
microbial agents. With effective antibiotics, the overall
mortality has decreased to 33% in adults with bacteremic
disease.3 This reduction in mortality is a considerable med-
ical success, but there is concern that these improvements
may be short-lived. Over the past 25 years there has been the
emergence and continued spread of S. pneumoniae with
antimicrobial resistance. Although there is no evidence
yet to suggest that antibiotic resistance has resulted in
increased mortality in hospitalized patients with pneumo-
coccal pneumonia, there is concern that in the near future it
may do so.
People who are immunocompromised are at particularly
high risk of invasive pneumococcal infections. For exam-
ple, persons infected with human immunodeficiency virus
(HIV) are estimated to be >100 times more susceptible to
invasive pneumococcal disease than age-matched con-
trols.4 The reason for the higher rate of disease in this
population has not been clearly delineated. Some believe
that immunocompromised patients are less able to elim-
inate pathogens once bacteremia has occurred. Others
think that their increased susceptibility to infection is
related to decreased mucosal surveillance allowing persis-
tent colonization. This notion is supported by the fact that
HIV patients have been shown to be persistently colonized
by the same strain of S. pneumoniae and the character-
istics of nasopharyngeal isolates are similar to those of
subsequent invasive strains.4,5 Regardless, the frequency
of severe pneumococcal disease in the immunocompro-
mised is concerning because the HIV epidemic coincides
with the emergence and global spread of antibiotic-
resistant pneumococcal strains. This is particularly true
in Sub-Saharan Africa where the prevalence of HIV infec-
tion is high and antibiotic alternatives to penicillin are
limited.
Because antibiotic choices are significantly governed by
cost rather than effectiveness in Uganda, there is an urgent
need to know the specific trends of antimicrobial resistance
in pneumococci in HIV patients. This cross-sectional study
addresses this issue by evaluating the prevalence of orophar-
yngeal colonization, the distribution of serotypes, and the
resistance patterns to antimicrobials of pneumococci at an
adult HIV clinic in Kampala.Materials and methods
Setting
The study was conducted at the HIV clinic at the Joint Clinical
Research Centre (JCRC) located in Kampala, Uganda. Kam-
pala is the capital city of Uganda covering an area of 169
square kilometers with a population of approximately one
million people. The JCRC was established in 1989 and has
become recognized as a center for excellence in HIV care in
Uganda and throughout Africa. The JCRC has state-of-the-art
laboratories, outpatient clinics, a pharmacy, and a 16-bed
inpatient ward. There is an HIV clinic that evaluates more
than 40 HIV-infected patients each day.
Participants
HIV-infectedUgandan adults (age 18 years or older) presenting
to the JCRC for clinical evaluation were invited to participate
in this cross-sectional study. The medical officers that care for
patients at the JCRC HIV clinic were responsible for recruiting
eligible HIV-infected men and women. Individuals were
excluded if they were over 55 years old, had received pneu-
mococcal vaccine within the past five years, were being
treated for active tuberculosis, or were taking antibiotics
for an acute infection at the time of enrollment. Patients
who were eligible and taking prophylactic antibiotics to pre-
vent opportunistic infections (OI), such as trimethoprim—sul-
famethoxazole (TMP—SMX), were not excluded. A
standardized questionnaire seeking data on demographics,
recent antibiotic treatment and prophylaxis, chronic medical
conditions, HIV treatment, prophylaxis for OIs, and hospitali-
zation was used. Between the months of July 2004 and Feb-
ruary 2005, a total of 600 HIV-infected adults were entered in
the study. Confirmation of HIV positive status and most recent
CD4 count were determined by chart review. Ethical approval
to conduct this study was obtained from the institutional
review board of Case Western Reserve University (CWRU)/
University Hospitals of Cleveland and the National Council of
ScienceandTechnology inKampala,Uganda.Written informed
consent was obtained from each patient prior to study entry.
Specimen collection and processing
Throat swabs were collected by the medical officers at the
JCRC from the posterior pharynx by inserting a BBL culture
swabplus (BectonDicksonMicrobiology Systems, Cockeysville,
MD, USA) through the oral cavity. The swabswere kept at room
temperature until being transported to a70 8C freezer at the
JCRC later on the same day the swab was collected. On a
monthly basis, the swabs were transferred from the freezer>99% were trimethoprim—sulfamethoxazole (TMP—SMX) resistant. Novel PCN intermediate ser-
otypes included 7, 11, 16, 20, 22, 24, and 34. Only one isolate was resistant to macrolides, and
resistance to other antibiotics was rare.
Conclusions: HIV-infected adults in Uganda are colonized with pneumococci that exhibit a high
degree of TMP—SMX and PCN non-susceptibility, with several unique PCN non-susceptible serotypes
that are not included in current vaccine preparations.
# 2006 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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freight to the laboratories at CWRU in accordance with local
and international shipment regulations.
At CWRU, the swabs were transferred from the liquid
nitrogen carriers into 70 8C freezers, where they were
stored until further analysis. The swabs were then thawed
and streaked onto trypticase soy agar (TSA) plates with 5%
whole sheep blood (Becton Dickson Microbiology Systems,
Cockeysville, MD, USA). An optochin disk (Becton Dickson
Microbiology Systems, Cockeysville, MD, USA) was placed in
the first streak area and plates were incubated overnight in
5% CO2 at 35 8C.
Identification, serotyping, and antimicrobial
susceptibility testing
Pneumococcal isolates were identified by a zone of inhibition
around the optochin disk and the presence of smooth, grey,
a-hemolytic colonies with depressed centers. Typical colo-
nies were then subcultured on fresh TSA blood plates and
incubated as previously outlined. The serogroups and sero-
types of the S. pneumoniae isolates were determined by
capsular swelling reaction, using antisera from Statens Serum
Institute of Copenhagen, Denmark. Antimicrobial suscept-
ibility patterns were determined by broth microdilution
minimum inhibitory concentration (MIC) determination,
according to Clinical and Laboratory Standards Institute
(CLSI) recommended procedures,6 using custom frozen
microdilution trays containing cation-adjusted Mueller—Hin-
ton broth supplemented with 5% lysed horse blood (TREK,
Westlake, OH, USA). The following agents were tested:
penicillin (PCN), amoxicillin, azithromycin, ceftriaxone,
cefuroxime, cefdinir, cefpodoxime, clindamycin, levofloxa-
cin and TMP—SMX. Trays were inoculated using an autoino-
culator (TREK) to deliver 100 mL/well, incubated under
ambient conditions at 35 8C for 20—24 h and the lowest
concentration of each agent showing no growth read as




Current smoker 3 (2.8)
Drinks alcohol 18 (16.7)
Child in household 89 (82.4)
Child age 1—2 years 11 (10.2)
Child age 3—5 years 28 (25.9)
Child age 6—10 years 57 (52.8)
Child age 11—18 years 72 (66.7)
Hospitalized in past two months 3 (2.8)
Upper respiratory infection in past two months 53 (49.1)
Taken antibiotics in the past two months 59 (54.6)
Had pneumonia in the past year 15 (13.9)
CD4 count <200 cells/mLb 89 (90.8)
Currently taking anti-retrovirals 71 (65.7)
Currently taking trimethoprim—sulfamethoxazole 69 (63.9)
a Reported as count data (%) except for age, which is shown as mea
b Of the 600 participants, 554 had a known CD4 count (colonizationinterpretative standards.6,7 PCR for mefA and ermB was
performed on azithromycin resistant isolates.8
Statistical analysis
Statistical analysis was performed using SAS software, ver-
sion 9.1 (SAS Institute Inc., Cary, NC, USA). Differences
between categorical variables were evaluated using x2 ana-
lysis, or, where appropriate, Fisher’s exact test. Differences
between continuous variables were evaluated using Stu-
dent’s t-test. A two-sided p value <0.05 was considered
significant for all comparisons.
Results
Study population
A total of 600 HIV-infected adults were sampled over a seven-
month period in 2004—2005. The age of the participants
ranged from 20 to 55 years old with a mean of 38.15 years
and a standard deviation of 7.5 years. Therewere 162menand
438 women included in the study. Out of the 554 participants
with known CD4 counts, 476 of them had CD4 counts less than
200 cells/mL. Seventy-eight percent (372/476) of patients
with a CD4 count <200 cells/mL and 2.6% (2/78) of patients
with a CD4 count >200 cells/mL were receiving highly active
anti-retroviral therapy (HAART). The most common regimen
was zidovudine/lamivudine/tenofovirwith 71.9% (269/374) of
those receiving HAART on this combination because of an
ongoing clinical trial at the facility. Additionally, 75.2%
(358/476) of patients with a CD4 count <200 cells/mL and
12.8% (10/78) with CD4 >200 cells/mL were taking TMP—SMX
for prophylaxis against opportunistic infections.
Prevalence of pharyngeal pneumococcal carriage
Overall, 18.0% (108/600) of participants were colonized with
pneumococci. The mean age of subjects who were colonizedtatus
iona (N = 108) No colonizationa (N = 492) p Value
















n (SD) in years.
N = 98; no colonization N = 456).
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who were not colonized (38.5 years) ( p = 0.035) (Table 1).
Oropharyngeal carriage did not vary by CD4 count, with 18.7%
(89/476) of the HIV patients having CD4 counts<200 cells/mL
and 11.5% (9/78) of the HIV patients having CD4 counts
>200 cells/mL being colonized ( p = 0.12). Taking prophylac-
tic TMP—SMX against opportunistic infections was not asso-
ciated with increased pneumococcal colonization.
Children in the household
Overall, 85.3% (512/600) of subjects reported having a child
living in their household, with 29.5% (177/600) of subjects
having at least one child less than five years old living in their
household. There was no significant association between
having children in the household and being colonized with
pneumococcus.
Antibiotic use in the previous three months
A total of 58.5% (351/600) of the participants reported that
they had received an antibiotic in the past three months. The
most commonly administered antibiotics were TMP—SMX
(70.4%, 247/351) and the penicillins (penicillin 3.1%, 11/351
and amoxicillin/ampicillin 22.5%, 79/351). Other agents,
including ciprofloxacin, chloramphenicol, erythromycin, and
tetracycline, were rarely utilized. Overall, 54.6% (59/108) of
the pneumococcal carriers and 59.3% (292/492) of the non-
carriers had received at least one antibiotic recently (Table 1).
This difference was not statistically significant (p = 0.39).
Hospitalization
A total of 47 subjects had a history of hospitalization in the
past two months. Of the participants, 19.0% (105/553) who
were not recently hospitalized and 6.4% (3/47) of those who
were recently hospitalized were colonized with pneumo-
coccus, suggesting that antimicrobial administration duringTable 2 Antimicrobial susceptibility of Streptococcus pneumonia
Agent Breakpoints b MIC range
(mg/mL)
Penicillin G 0.06/0.12—1/2 0.015—0.5
Penicillin G, high dose IVd 1/—/2 0.015—0.5
Amoxicillin 2/4/8 0.015—2
Azithromycin 0.5/1/2 0.03—4
Ceftriaxone, non-meningitis 1/2/4 0.015—0.5
Ceftriaxone, meningitis 0.5/1/2 0.015—0.5
Cefuroxime, parenteral 0.5/1/2 0.03—2






aReported as No. (percentage) of strains.
bSusceptible/intermediate/resistant breakpoints in mg/mL based on CL
values are shown as trimethoprim component and intermediate values
dHigh doses of IV penicillin G (at least 2 million units every 4 h in adults
pneumonia due to strains with penicillin G MICs 1 mg/mL.1,6hospitalization may have eradicated pneumococcal carriage
(OR = 0.29, 95% CI 0.089—0.955, p = 0.03).
Antimicrobial susceptibility
A total of 109 pneumococci were isolated from 108 partici-
pants, with one of the participants carrying two distinct
pneumococcal isolates (Table 2). Overall, 28.4% (31/109) of
the pneumococcal isolates were PCN susceptible (MICs 0.06
mg/mL) and 71.6% (78/109) were PCN intermediate (MICs
0.12—0.5 mg/mL). There were no PCN resistant isolates (MICs
2 mg/mL). Based on current interpretative breakpoints, all
isolates are susceptible to penicillin G at a dose of at least 2
million units every 4 h for adults with pneumococcal pneumo-
nia,while only PCN sensitive isolates (28.4%) are susceptible in
patients with pneumococcal meningitis. There were no iso-
lates resistant to amoxicillin, ceftriaxone (at both meningeal
and non-meningeal breakpoints), clindamycin or levofloxacin.
Of the other cephalosporins tested, 95.4% of isolates were
susceptible to cefuroximebased onparenteral administration,
while >98% were susceptible to cefuroxime based on oral
administration and the oral cephalosporins, cefdinir and cef-
podoxime. Almost all isolates (108/109) were TMP—SMX resis-
tant (MICs1 mg/mL) with MICs ranging from 2.0 to>4.0 mg/
mL. Only one isolate was resistant to macrolides, with an
azithromycinMIC of 4 mg/mL, and it contained themefA gene,
which codes for efflux-mediated macrolide resistance.
Use of any antibiotic within the past two months was not
associated with colonization but was associated with carriage
of a PCN non-susceptible pneumococcus ( p = 0.029). Mean-
ingful subgroup analysis of PCN non-susceptibility based on
exposure to particular antibiotics could not be done due to
insufficient sample sizes. There were no other demographic
risk factors associated with either PCN non-susceptibility or
TMP—SMX resistance.
A total of 43.5% (47/108) of the subjects with TMP—SMX
resistance were taking TMP—SMX at the time of enrollment.




0.25/0.5 31 (28.4) 78 (71.6) 0
0.25/0.5 109 (100) — 0
0.12/0.25 109 (100) 0 0
0.06/0.12 108 (99.1) 0 1 (0.9)
0.06/0.12 109 (100) 0 0
0.06/0.12 109 (100) 0 0
0.25/0.5 104 (95.4) 4 (3.7) 1 (0.9)
0.25/0.5 108 (99.1) 1 (0.9) 0
0.12/0.25 107 (98.2) 1 (0.9) 1 (0.9)
0.12/0.25 108 (99.1) 1 (0.9) 0
6 0.03/0.06 109 (100) 0 0
0.5/1 109 (100) 0 0
4/>4 1 (0.9) — 108 (99.1)
SI breakpoints, except for ctrimethoprim—sulfamethoxazole where
are combined with resistant.6,7
with normal renal function) are effective in treating pneumococcal
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Figure 1 Frequency of pneumococcal serogroups and penicillin susceptibility (N = 109).were taking penicillin at the time. The one TMP—SMX sus-
ceptible isolate was also PCN susceptible. The one isolate
that was macrolide resistant was also resistant to TMP—SMX.
Serotype and resistance pattern distribution
Thirty-two pneumococcal serotypes were identified in the
109 isolates. Themost commonwere serotypes 3 (14.7%), 19F
(6.4%), 23F (6.4%), and 16 (5.5%) (Figure 1). Of the serotype 3
isolates, 92% occurred in participants with CD4 <200 cells/
mL, and all 16 serotype 3 isolates were PCN non-susceptible.
There were five serotype 29 pneumococci identified, all of
which were intermediate to PCN. Novel PCN intermediate
serotypes included 7, 11, 16, 20, 22, 24, and 34. Thirty
percent of the isolates belonged to the common pediatric
serogroups 6, 9, 14, 19, and 23. Twenty-six percent (28/109)
of the pneumococci and 28.2% (22/78) of the PCN intermedi-
ate isolates are covered by the seven-valent conjugate vac-
cine. Fifty-two percent (57/109) of the pneumococci and
64.1% (50/78) of the PCN intermediate isolates are covered
by the 23-valent polysaccharide vaccine. The one macrolide
resistant isolate belonged to serotype 18C.
Discussion
Pneumococcal disease is a significant cause of morbidity and
mortality in adults infected with HIV.4 Because invasive
infection likely follows nasopharyngeal and oropharyngeal
colonization, important information can be ascertained from
the strains that colonize this patient population. Our study
shows that the prevalence of oropharyngeal colonization
with pneumococci in HIV-infected adults visiting an HIV clinic
in Uganda was 18%. Although there are few data regarding
the prevalence of pneumococcal colonization in HIV-infected
adults, our results are consistent with a recent longitudinal
study done in the USA that suggests that between 12.6% and
22.2% of HIV-infected adults have oropharyngeal colonization
with pneumococci at any particular point in time.4
The pneumococcal isolates in our study showed a high
degree of antibiotic resistance, especially to TMP—SMX and
PCN. The presence of TMP—SMX resistance is not surprising
because TMP—SMX resistance is known to be widespread
around the world.1 Nonetheless, the high prevalence of
resistance at a level greater than 99% is impressive. Recent
studies show that TMP—SMX resistance in pneumococcal
isolates is in the range of 30% in the USA.2,9 In Africa, a
study of 160 pneumococcal isolates from cases of invasive
disease in all age groups in Zimbabwe showed resistance of>50%,10 while a study of isolates in South Africa in 1997
showed resistance >64%.11 The only study to approach the
level of TMP—SMX resistance seen in our study was an evalua-
tion done by Joloba et al. in 1995 of 115 strains in Ugandan
children that showed a resistance prevalence of 83.5%.5
While studies from around the world have also shown large
variations in PCN resistance patterns (0—79% non-suscepti-
ble) between various countries,12,13 it is well documented
that PCN resistance in pneumococci has been increasing
globally. In the USA, studies have shown that between 20%
and 35% of pneumococcal isolates are now non-suscepti-
ble.9,14 A large study of invasive pneumococcal disease in
South Africa showed PCN resistance in all ages had increased
to 18%.15 In East Africa, most of the studies have been done
on nasopharyngeal colonization of pneumococci in chil-
dren.5,16 Just as has been seen with TMP—SMX, the preva-
lence of resistance to PCN in this part of the world appears to
be on the higher end of the global spectrum. While a study of
Kenyan children showed intermediate PCN resistance in 60%
of 94 pneumococcal isolates,16 Joloba et al. showed 83.5% of
115 isolates had intermediate PCN resistance in Uganda in
1995.5
One possible cause for the high resistance to PCN and
TMP—SMX in the HIV-infected patients in our study is that
these strains are prevalent in people of all ages in Uganda.
The adults in the HIV clinic, however, have other reasons that
may also contribute to these high levels of resistance. For one
thing, there is evidence to suggest that comorbid conditions
such as HIV disease itself, is associated with PCN non-suscep-
tible pneumococcal infections.17,18 Although our study did
not evaluate this factor, other studies of invasive pneumo-
coccal disease, some of which have been done in Africa, have
shown that HIV-infected patients have infections with pneu-
mococci with a higher proportion of PCN non-susceptibility
than HIV negative patients. For example, Gwanzura et al.
showed that 50% of isolates from HIV-infected individuals in
Zimbabwe compared to 16% of HIV negative individuals were
infected with PCN non-susceptible strains.10 In addition, a
study of invasive disease in Kenyan adults showed that the
PCN non-susceptibility rate in HIV positive individuals was
27% compared to 7% in HIV negative subjects.19
The population of HIV-infected adults in our study is also
frequently exposed to these two commonly prescribed anti-
biotics. For example, 75.2% of patients with a CD4 count
<200 cells/mL were taking TMP—SMX as OI prophylaxis. In
addition, the penicillins are some of the cheapest and most
readily available antibiotics in Uganda and Ugandans, accord-
ing to Ugandan physicians, self-medicate liberally for their
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present to the clinic if their own efforts at cure from local
pharmacies are ineffective. Our study found an association
between recent use of any antibiotic and PCN non-suscept-
ibility. Because the sample sizes were too small, it was not
possible to do subgroup analysis to see if particular antibio-
tics were associated with PCN non-susceptibility. Other stu-
dies have, however, shown that PCN non-susceptibility is
associated with recent penicillin use.20
All of the isolates in our study that were non-susceptible to
PCN were also resistant to TMP—SMX. Although the reason for
this association is not well delineated (since their mechan-
isms of resistance are different), it has been well documen-
ted that TMP—SMX and PCN non-susceptibility frequently
occur in the same isolate.21 While multi-drug resistance is
becoming more prevalent in other parts of the world such as
in the USA, where rates are as high as 14%, there were no
isolates in our study with multi-drug resistance.2 In addition,
the one isolate with macrolide resistance in our study was
found to have the mefA gene. The isolation of this gene in
Uganda is noteworthy because the ermB gene is the one more
commonly found outside of the USA.11
There are several limitations to this study. Only HIV-
infected adults at one clinic in Uganda were sampled. As a
result, it may not be reasonable to generalize these results to
the population, or even to other HIV clinics in East Africa.
Because the study was conducted at an HIV clinic, no HIV
negative adults participated, so we are not able to discuss the
role that HIV status plays in the rates of oropharyngeal
colonization. In addition, oropharyngeal swabs rather than
nasopharyngeal swabs, or both, were collected. A recent
study byWatt et al. demonstrated that nasopharyngeal swabs
are more sensitive than oropharyngeal swabs in adults, and
that collecting samples from both sites is optimal.22
It is also worthmentioning that no association was found in
this small study between pneumococcal colonization and the
classic risk factors for colonization that have been detailed in
other studies, such as smoking, the presence of chronic
diseases, and the presence of young children in the house-
hold. Instead, our study found an association between
younger age and higher prevalence of colonization. The
reasons for this association are not clear, but the fact that
there were significantly more women enrolled in the study
than men may have had an influence. In addition, the results
of our study suggested that subjects who were recently
hospitalized had a lower rate of colonization. One possible
explanation is that these subjects were given antibiotics in
the hospital that cleared their carriage.
Our study provides compelling and important information
related to the susceptibility and unique serotype distribution
of pneumococci colonizing HIV-infected adults in Uganda.
Our results support the use of penicillin G and ceftriaxone
parenterally for non-meningeal infections, as all isolates
were susceptible based on non-meningeal breakpoints. How-
ever, while ceftriaxone is a suitable option for pneumococcal
meningitis, penicillin G is not as cerebrospinal fluid levels are
too low to be effective against PCN intermediate strains. Our
results support the use of amoxicillin and macrolides as first-
line oral agents for empiric treatment of disease likely to be
caused by pneumococci in Uganda. Selected oral cephalos-
porins can be used empirically to treat pneumococcal disease
in Uganda as >98% of isolates were susceptible to the oralcephalosporins tested, but these agents have no advantage
over amoxicillin.
Serotyping showed that therewere32 serogroups identified
in 109 isolates, with rare serotypes, such as serotype 29,
representing 4.6% (5/109) of the isolates. In addition, 70%
of the isolates did not belong to any of the common pediatric
serogroups, and isolates of seven rare serotypes, 7, 11, 16, 20,
22, 24,and34, showednovel PCNnon-susceptibility.Our study,
therefore, suggests that an array of less common serotypes is
circulating among this high-risk population of patients.
Serotype 3 was the most common serotype isolated, and
all of the serotype 3 isolates were PCN intermediate. Ser-
otype 3 is known to be more common in adults than in
children,1 so the high prevalence in this study may not be
surprising. Whether the emergence of PCN non-susceptibility
in this serotype is related to the HIV status of these indivi-
duals or to other factors is not known. The PCN non-suscep-
tible serotype 3 isolates have been reported from the USA,
Taiwan, Kenya, Italy, and France.23
Past studies in the pre-HAART era have shown that the
polysaccharide vaccine was not effective in HIV-infected
adults.24 Our study may complicate matters even further
because it suggests that only a small portion of the colonizing
serotypes in Uganda are included in any of the current
vaccine preparations. For example, only 52% of the serotypes
identified in our study are included in the 23-valent poly-
saccharide vaccine preparation, and only 26% of the sero-
types identified in our study are included in the seven-valent
conjugate vaccine preparation. A counter argument to this
may be that several of the serotypes identified in our study
are colonizers without the capability of invasive disease.
Either way, our results give more support to the concept
that the prospects for controlling pneumococcal disease in
Uganda in the near future by immunization are challenging.
Ultimately, therefore, it may be worthwhile to continue to
monitor the serotypes and antibiotic susceptibilities in this
HIV-infected population of patients, since these individuals
are at high risk for poor outcomes with invasive pneumococ-
cal disease. To investigate this specific issue, a reasonable
future study would be to conduct a case-control study in
Kampala, Uganda of invasive pneumococcal disease in HIV-
infected and HIV-non-infected adults to detect differences in
pneumococcal characteristics between these two patient
populations.
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